3-bromo-5-phenyl Salicylic Acid
mRNA synthesis
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
Tyramide Signal Amplification (TSA)
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Phos Binding Reagent Acrylamide
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
Cell Counting Kit-8 (CCK-8)
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
SYBR Safe DNA Gel Stain
Safe and sensitive stain for visualization of DNA or RNA in agarose or acrylamide gels.
Inhibitor Cocktails
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
Ki: 140 nM for AKR1C1; 1.97 μM for AKR1C2; 21 μM for AKR1C3
3-bromo-5-phenyl Salicylic acid is an AKR1C1 inhibitor.
The aldo-keto reductase (AKR) enzymes are a family of related NADP-dependent oxidoreductases, in which The 1C subfamily (AKR1C) has 4 human hydroxysteroid dehydrogenases (HSD), a 20α-HSD and the other three being 3α-HSDs. AKR1C1 has been found to metabolize progesterone to 20α-hydroxy progesterone, its inactive progestin.
In vitro: In previous screening study, the additional phenyl group of 3-bromo-5-phenylsalicylic acid, targeting a nonconserved hydrophobic pocket in the active site of AKR1C1, resulted in 21-fold improved potency over the structurally similar 3alpha-hydroxysteroid dehydrogenase isoform (AKR1C2). 3-bromo-5-phenyl Salicylic acid was found to be hydrogen bonded to His117, Tyr55, and His222, and the phenyl ring could form additional van der Waals interactions with residues Phe311, Leu308, and Leu54. In addition, the metabolism of progesterone in AKR1C1-overexpressed cells could be potently inhibited by 3-bromo-5-phenylsalicylic acid, which was effective from 10 nM to 460 nM [1].
In vivo: Up to now, there is no animal in vivo data reported.
Clinical trial: So far, no clinical study has been conducted.
Reference:
[1] El-Kabbani, O. ,Scammells, P.J.,Gosling, J., et al. Structure-guided design, synthesis, and evaluation of salicylic acid-based inhibitors targeting a selectivity pocket in the active site of human 20α-hydroxysteroid dehydrogenase (AKR1C1). Journal of Medicinal Chemistry 52, 3259-3264 (2009).
| Physical Appearance | A crystalline solid |
| Storage | Store at -20°C |
| M.Wt | 293.1 |
| Cas No. | 4906-68-7 |
| Formula | C13H9BrO3 |
| Synonyms | NSC 109116 |
| Solubility | ≤0.1mg/ml in ethanol;12.5mg/ml in DMSO;15mg/ml in dimethyl formamide |
| Chemical Name | 5-bromo-4-hydroxy-[1,1'-biphenyl]-3-carboxylic acid |
| SDF | Download SDF |
| Canonical SMILES | BrC1=CC(C2=CC=CC=C2)=CC(C(O)=O)=C1O |
| Shipping Condition | Evaluation sample solution: ship with blue ice. All other available sizes: ship with RT, or blue ice upon request. |
| General tips | For obtaining a higher solubility, please warm the tube at 37°C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months. |
Quality Control & MSDS
- View current batch:
-
Purity ≥ 95.00%
- COA (Certificate Of Analysis)
- MSDS (Material Safety Data Sheet)
Chemical structure
